Founder of ImmuneOnco Biopharmaceuticals (Shanghai) Tian Wenzhi Buys More Stock

Potential ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) shareholders may wish to note that the Founder, Tian Wenzhi, recently bought HK$792k worth of stock, paying HK$5.28 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

The Last 12 Months Of Insider Transactions At ImmuneOnco Biopharmaceuticals (Shanghai)

In fact, the recent purchase by Tian Wenzhi was the biggest purchase of ImmuneOnco Biopharmaceuticals (Shanghai) shares made by an insider individual in the last twelve months, according to our records. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of HK$6.59. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Check out our latest analysis for ImmuneOnco Biopharmaceuticals (Shanghai)

ImmuneOnco Biopharmaceuticals (Shanghai) is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that ImmuneOnco Biopharmaceuticals (Shanghai) insiders own 17% of the company, worth about HK$468m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About ImmuneOnco Biopharmaceuticals (Shanghai) Insiders?

The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest ImmuneOnco Biopharmaceuticals (Shanghai) insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing ImmuneOnco Biopharmaceuticals (Shanghai). While conducting our analysis, we found that ImmuneOnco Biopharmaceuticals (Shanghai) has 1 warning sign and it would be unwise to ignore it.

But note: ImmuneOnco Biopharmaceuticals (Shanghai) may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.